2023
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.Peer-Reviewed Original ResearchConceptsBaseline kidney functionKidney composite outcomeEffect of dapagliflozinEjection fractionHeart failureKidney outcomesComposite outcomePrimary outcomeKidney functionKidney diseaseSodium-glucose cotransporter 2 inhibitorsBaseline eGFR categoryBaseline kidney diseaseBenefit of dapagliflozinComposite kidney outcomeHeart Failure TrialReduced ejection fractionCotransporter 2 inhibitorsHeart failure eventsGlomerular filtration rateOverall incidence rateOverall event rateLives of patientsTreatment effectsEGFR categories
2022
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER
Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBlood pressureHeart failureSBP categoriesEjection fractionPrimary outcomeKansas City Cardiomyopathy Questionnaire total symptom scoreTreatment effectsSodium-glucose cotransporter 2 inhibitorsBaseline systolic blood pressureBlood pressure-lowering effectHigher systolic blood pressureHigher heart failureClass I recommendationCotransporter 2 inhibitorsPressure-lowering effectTotal symptom scoreCardiovascular outcomesAdverse eventsAntihypertensive effectSecondary outcomesStroke riskI recommendationSymptom scoresCardiovascular disease
2014
The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study
Hoang QN, Pisani MA, Inzucchi S, Hu B, Honiden S. The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. Journal Of Critical Care 2014, 29: 1052-1056. PMID: 25092614, DOI: 10.1016/j.jcrc.2014.06.007.Peer-Reviewed Original ResearchConceptsBaseline glycemic controlStress hyperglycemiaGlycemic controlUndiagnosed diabetesChronic Health Evaluation II scoreMedical intensive care unit patientsIntensive care unit patientsHemoglobin A1c levelsHistory of diabetesObservational cohort studyProspective observational studyUndiagnosed diabetes mellitusCare unit patientsIntensive care unitLower baseline HbA1cMultivariable logistic regressionSignificant differencesAcute PhysiologyHospital mortalityNondiabetic patientsBaseline HbA1cII scoreMICU patientsCohort studyCritical illness
2001
The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy
Novella S, Inzucchi S, Goldstein J. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle & Nerve 2001, 24: 1229-1231. PMID: 11494278, DOI: 10.1002/mus.1137.Peer-Reviewed Original ResearchConceptsIdiopathic sensory neuropathyAbnormal glucose metabolismUndiagnosed abnormal glucose metabolismPainful symptomsSensory neuropathyGlucose metabolismOral glucose tolerance testComparison of patientsGlucose tolerance testUndiagnosed diabetesGlucose toleranceTolerance testPatientsNeuropathySymptomsP-valueMetabolismDiabetesHigh frequency